Exelixis is on a Mission to Help Cancer Patients Recover Stronger and Live Longer

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need.

Learn More

Exelixis Medical Affairs

Exelixis is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new products for difficult-to-treat cancers. Discovery efforts have resulted in four approved products available worldwide. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.

Learn More

KidneyCAN thanks Exelixis for their generous support for KCRS21 as a Founding Partner.

KidneyCAN Platinum Guidestar Seal

KidneyCAN is a registered 501(c)(3) nonprofit grassroots organization dedicated to funding and finding a cure for kidney cancer.

Contact KidneyCAN

KidneyCAN, 8327 Germantown Avenue, Philadelphia, PA 19118